IL17A and liver dysplastic nodule: Recently, we described that administration of a neutralizing anti-IL-17A antibody to BTBR ob/ob mice after kidney disease development reversed the structural abnormalities of DN, including amelioration of mesangial matrix accumulation, renal inflammation mitigation, and improved renal function [72], suggesting that IL-17A blockade could be a potential therapeutic option for DN.